BC Innovations | Dec 20, 2019
Distillery Therapeutics

CAPN3 gene therapy for limb-girdle muscular dystrophy type 2A

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy An adeno-associated viral vector deliverying CAPN3, a calcium-dependent protease expressed at low levels in the heart and primarily expressed in skeletal muscle, could treat limb-girdle muscular dystrophy type 2A...
BC Extra | Sep 26, 2019
Company News

Blade eyeing fibrosis combos with acquisition of PharmAkea-spinout

Blade is adding to its fibrosis pipeline with the acquisition of PharmAkea-spinout ATXco Inc. and its autotaxin inhibitor PAT-409. President and CEO Wendye Robbins said PAT-409 is complementary to Blade Therapeutics Inc.’s BLD-2660, a calpain...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

Inhibiting CAPN9 to treat fibrosis

DISEASE CATEGORY: Pulmonary; hepatic; cardiovascular INDICATION: Pulmonary fibrosis; liver fibrosis; cardiac fibrosis Inhibition of CAPN9 could treat fibrosis by blocking a TGFβ-induced pathway that contributes to fibrosis development. Two tool compound CAPN9 inhibitors decreased TGFβ-induced...
BC Extra | Jul 19, 2019
Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation  Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
BC Innovations | Aug 25, 2016
Distillery Therapeutics

Therapeutics: Calpain 6 (CAPN6)

Cardiovascular disease INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting CAPN6 could help treat atherosclerosis. In patients, CAPN6 expression on macrophages in atheromas was associated with disease severity. In a mouse model of atherosclerosis,...
BC Innovations | Dec 18, 2014
Distillery Techniques

Techniques: Chromosome 11 open reading frame 30 (C11orf30),calpain small subunit 1 (CAPNS1; CAPN14), signal transducer and activator oftranscription 6 (STAT6)

Bio Markers TECHNOLOGY: Markers Genomewide association studies identified four genes that could serve as diagnostic markers and/or therapeutic targets for EoE. In a discovery cohort of 603 EoE patients and 3,637 controls, variants at C11orf30...
BC Innovations | Jul 31, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); neurology Calpain; calpastatin Mouse studies suggest inhibiting calpain could help treat AD and other neurodegenerative tauopathies. In a transgenic mouse tauopathy model,...
BC Innovations | Jan 9, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve injury Calpastatin; calpain In vitro and mouse studies suggest calpastatin, an inhibitor of the proteinase calpain, could help treat nerve injury. In cultured mouse...
BC Innovations | Apr 5, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Calpain 2 (CAPN2) In vitro and mouse studies suggest CAPN2 inhibitors could help treat breast cancer. In a mouse mammary cancer cell line,...
BC Innovations | Nov 3, 2011
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Calpain small subunit 1 (CAPNS1; CAPN4) In vitro and rodent studies suggest inhibiting calpain could help treat pulmonary arterial hypertension (PAH). In smooth...
Items per page:
1 - 10 of 43